Elina Armani Khatibi
1 
, Tooba Gholikhani
1,2* , Balam Jimenez Brito
3, Nastaran Farshbaf Moghimi
41 Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
2 Nanora Pharmaceuticals Ltd, Tabriz, Iran
3 Victoria University of Wellington, School of Biological Sciences, Wellington, New Zealand
4 Department of Pharmaceutics, School of Pharmacy, Ardabil University of Medical Science, Ardabil, Iran
Abstract
Triple-negative breast cancer (TNBC) is considered one of the most aggressive forms of BC, which increases the risk of cancer-associated death. Despite the availability of specifically targeted medications for treating TNBC with HER2-positive or hormone receptor-positive cancers, chemotherapy is still the mainstay of treatment. Sacituzumab, an antibody-drug conjugate (ADC), targets tumor-associated calcium signal transducer 2 (Trop-2)-expressing cells and presents biologically active metabolites of irinotecan hydrochloride (SN-38). This review evaluates the effectiveness and safety of Sacituzumab in treating metastatic or previously treated TNBC in patients. According to the National Center for Biotechnology Information website, another epithelial metastasis has been included in data on clinical trials and sacituzumab. Sacituzumab has hopeful antitumor effects on patients with metastatic TNBC treated with at least two treatment lines, according to a clinical trial that is in phase I/II. Sacituzumab has a controllable adverse effect, with neutropenia, nausea, and diarrhea being the most frequent negative side effects. As a result of these promising early efficacy data, Sacituzumab’s activity may develop in TNBC, as well as various other epithelial tumors, such as hormone receptor-positive BC.